Shots:

• The P-III TOURMALINE-MM4 study involves assessing Ninlaro (ixazomib) as 1L maintenance therapy vs PBO in 706 newly diagnosed patients with multiple myeloma not treated with stem cell transplantation with completed 6-12mos. of initial therapy and achieved a partial response or better
• The P-III TOURMALINE-MM4 study results demonstrated significant improvement in PFS with consistent safety profile with previous results of Ninlaro used as a single agent and no new safety signals were identified
• Ninlaro is an oral proteasome inhibitor being evaluated in multiple therapeutic combinations globally and has received FDA’s approval in combination with lenalidomide and dexamethasone for patients with MM who have received at least one prior therapy in Nov’2015

Click here to­ read full press release/ article 

Ref: Takeda  | Image: Takeda